Targeting menin for precision therapy in high-risk acute myeloid leukemia
{{output}}
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancemen... ...
